Start with its own history
At 25.38×, JNJ is 48.0% below its 10-observation annual average. A lower multiple can reflect a lower price, higher earnings, or weaker growth expectations—not necessarily a bargain.
NYSE · JNJDrug Manufacturers - GeneralUpdated Nov 5, 2026
Johnson & Johnson P/E ratio
Current valuation, historical context, and peer comparisons.
Current P/E ratio
25.38×
48.0% belowthe 10-year annual average
Share price272.32
÷Earnings per share10.73
Price and EPS in quote currency. Calculation details
Investors are paying 25.38 for every 1 of reported earnings per share.
P/E over time
2016 – 2025
Annual P/ESelected-period average 48.80×
3-year average18.22×3 positive annual observations
5-year average20.43×5 positive annual observations
10-year average48.80×10 positive annual observations
Peer median · TTM29.14×8 peers with positive P/E
Historical P/E ratios
Annual period-end data · 25 observations
| Period end | P/E | Change |
|---|---|---|
| Dec 28, 2025 | 18.82× | -23.3% |
| Dec 29, 2024 | 24.54× | +117.4% |
| Dec 31, 2023 | 11.29× | -56.3% |
| Jan 1, 2023 | 25.86× | +19.6% |
| Jan 2, 2022 | 21.63× | -22.7% |
| Jan 3, 2021 | 28.00× | +10.2% |
| Dec 31, 2019 | 25.41× | +13.2% |
| Dec 31, 2018 | 22.44× | -92.3% |
View all 25 annual observations +
| Period end | P/E | Change |
|---|---|---|
| Dec 31, 2017 | 291.08× | +1436.1% |
| Dec 31, 2016 | 18.95× | +2.8% |
| Dec 31, 2015 | 18.44× | +3.3% |
| Dec 31, 2014 | 17.84× | -4.5% |
| Dec 31, 2013 | 18.69× | +4.3% |
| Dec 31, 2012 | 17.93× | -3.2% |
| Dec 31, 2011 | 18.53× | +45.6% |
| Dec 31, 2010 | 12.73× | -12.1% |
| Dec 31, 2009 | 14.47× | +13.0% |
| Dec 31, 2008 | 12.81× | -29.5% |
| Dec 31, 2007 | 18.17× | +3.5% |
| Dec 31, 2006 | 17.56× | -1.3% |
| Dec 31, 2005 | 17.78× | -22.9% |
| Dec 31, 2004 | 23.06× | +8.0% |
| Dec 31, 2003 | 21.35× | -12.6% |
| Dec 31, 2002 | 24.41× | -22.8% |
| Dec 31, 2001 | 31.60× | N/M |
Change is relative to the preceding observation. N/M values are excluded from averages.
How JNJ compares
Company P/E vs. peer trailing-12-month ratios
| Company | P/E ratio |
|---|---|
 JNJ This stockJohnson & Johnson | 25.38× |
 MRKMerck & Co., Inc. | 149.93× |
 AZNAstraZeneca PLC | 26.53× |
 PFEPfizer Inc. | 42.54× |
 NVSNovartis AG | 31.59× |
 GSKGSK plc | 17.50× |
 SNYSanofi | 24.22× |
 AMGNAmgen Inc. | 26.68× |
 ABBVAbbVie Inc. | 49.67× |
Peers are selected by the data provider. Business models and earnings definitions can differ.
Put the numbers in context
What does JNJ’s P/E tell you?
Compare like with like
The median of the 8 positive peer ratios above is 29.14×. Check growth, margins, debt, and earnings quality before interpreting the gap. A faster-growing business may justify a higher multiple.
Check what drives earnings
One-off gains can temporarily lower P/E; unusual charges can raise it. Reported earnings and forward estimates answer different questions. Pair this view with return on equity and liquidity for a fuller picture.
Keep your research connected
Take JNJ into your spreadsheet
Pull historical P/E into Excel or Google Sheets with Wisesheets. Build your own comparisons alongside the rest of your financial model.
Explore WisesheetsQuarterly P/E · latest quarterLQ selects the latest reported quarter. Requires the Wisesheets add-in. See available data
=WISE("JNJ", "PE Ratio", "LQ")Sources & calculation methodology
Current P/E
Share price 272.32 ÷ EPS 10.73 = 25.38×. Data is supplied by Financial Modeling Prep through Wisesheets. Quote feed updated Nov 5, 2026; this is not a real-time trading quote.
History & averages
Annual and quarterly P/E observations are provided separately from the current quote. Averages use the latest 3, 5, or 10 annual observations, excluding missing and nonpositive ratios. Pre-IPO observations are omitted. These are period-end observations, not daily averages.
Data definitions and limitations
The current quote feed does not specify the exact EPS filing-period end or whether EPS is basic or diluted. We do not label it as forward P/E. Peer ratios are explicitly trailing-12-month (TTM) values. Historical observations do not include independently verified price and EPS inputs. Sources may update on different schedules; rounded inputs can produce small calculation differences. Historical comparisons describe past pricing, not an estimate of fair value.
JNJ P/E ratio: common questions
The essentials behind the numbers.
Johnson & Johnson's current P/E is 25.38× based on the quote data last updated Nov 5, 2026. It represents the share price divided by reported earnings per share. Prices and earnings may refresh on different schedules.
Annual P/E uses earnings for a completed fiscal year. Trailing-12-month (TTM) P/E uses the latest four quarters, while forward P/E uses forecast earnings. These are not interchangeable. This page labels peer ratios as TTM and shows dated annual or quarterly historical observations; it does not show forward estimates.
N/M means not meaningful: the feed has no positive P/E for that observation. Negative or zero earnings should not be ranked as a low positive valuation multiple. N/M observations are excluded from the averages shown above.
Divide the share price by earnings per share (EPS). For example, a share price of 100 and EPS of 5 gives a P/E of 20×. This page uses the price and EPS supplied together in the quote when both are positive.
Price timestamps, EPS definitions, share classes, adjustments, and fiscal periods can differ. A forward P/E also uses forecast earnings rather than reported earnings. Compare the inputs and as-of dates before comparing two displayed ratios.
Not necessarily. The average describes previous market pricing, not fair value. Changes in earnings quality, growth expectations, debt, accounting, and business risk can justify a different multiple today.